These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17989655)

  • 1. Lack of data mires Aranesp in controversy.
    Wadman M
    Nat Biotechnol; 2007 Nov; 25(11):1193. PubMed ID: 17989655
    [No Abstract]   [Full Text] [Related]  

  • 2. Rebates for anti-anemia drugs draw response from FDA, CMS.
    Sipkoff M
    Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
    [No Abstract]   [Full Text] [Related]  

  • 3. Erythropoietin, the FDA, and oncology.
    Steinbrook R
    N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
    [No Abstract]   [Full Text] [Related]  

  • 4. Biosimilar epoetins.
    Macdougall IC
    Nephrol Dial Transplant; 2009 May; 24(5):1698-9; author reply 1699-700. PubMed ID: 19366858
    [No Abstract]   [Full Text] [Related]  

  • 5. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
    Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
    Yang MC
    Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
    [No Abstract]   [Full Text] [Related]  

  • 7. Darbepoetin alpha is highly cost-effective compared with epoetin alpha in the treatment of renal anemia: a brief report from a hemodialysis clinic in Japan.
    Nakagawa T
    Ther Apher Dial; 2008 Dec; 12(6):531-2. PubMed ID: 19140854
    [No Abstract]   [Full Text] [Related]  

  • 8. Managing anemia: what do we do now?
    Neumann ME
    Nephrol News Issues; 2007 May; 21(6):50, 52. PubMed ID: 17518123
    [No Abstract]   [Full Text] [Related]  

  • 9. A star rises, another fades.
    Neumann ME
    Nephrol News Issues; 2013 Jul; 27(8):8. PubMed ID: 23926618
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythropoietin: high profile, high scrutiny.
    Crawford J
    J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
    [No Abstract]   [Full Text] [Related]  

  • 11. [Switch from Darbepoetin-alpha to Epoetin-alpha: cost and efficacy comparison for haemodialytic patients over one year follow-up in a single centre].
    Orazi E
    G Ital Nefrol; 2008; 25(2):223-6. PubMed ID: 18350502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin claims monitoring policy: implications of the October 2006 update continuing.
    Messana T
    Nephrol Nurs J; 2006; 33(6):660-3; quiz 664-5. PubMed ID: 17219727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost analysis of erythropoietic-stimulating therapy dosing in oncology inpatients.
    Killian AD; Gupta V; Goetz AE
    Ann Pharmacother; 2006 Mar; 40(3):421-6. PubMed ID: 16507613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative studies on erythropoietic agents.
    Straus D
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S46-9. PubMed ID: 16280113
    [No Abstract]   [Full Text] [Related]  

  • 16. [Epoietins (EPO)].
    Taeron C
    Rev Infirm; 2007 Oct; (134):55-6. PubMed ID: 18087795
    [No Abstract]   [Full Text] [Related]  

  • 17. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
    Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
    Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin alfa and darbepoetin alfa go head to head.
    Steensma DP; Loprinzi CL
    J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
    [No Abstract]   [Full Text] [Related]  

  • 19. Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins.
    Pujade-Lauraine E; Topham C
    Oncology; 2005; 68(2-3):122-9. PubMed ID: 16015034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin claims monitoring policy: implications for clinical practice.
    Messana T
    Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.